ALFA Finder
| MoU Value | ₹500 CrProposed Investment |
|---|---|
| Market Cap | ₹9,347 CrMid Cap |
| P/E TTM | 32.76Sector: 43.78 |
| Revenue Growth | 127.1%YoY (Latest Qtr) |
| Execution period | MoU valid for 12 months from the date of signing |
| Deal value | ₹500 Cr |
| Share of market cap | 5.3% |
| Share of annual revenue | 45.6% |
Key highlights
- MoU signed on November 13, 2026, with the Andhra Pradesh Economic Development Board (APEDB)
- Proposed investment of ₹500 crore for setting up an API manufacturing facility
- Evaluation of 50 acres of land acquisition to be conducted in a phase-wise manner
- Agreement is non-binding and valid for a period of 12 months from the date of signing
- Project remains subject to statutory clearances, government policies, and board approval
Strategic Expansion in Andhra Pradesh
Blue Jet Healthcare's partnership with the Andhra Pradesh Economic Development Board marks a significant intent to scale its Active Pharmaceutical Ingredient manufacturing footprint. The proposed ₹500 crore investment represents approximately 45.6 percent of the company's trailing twelve-month revenue of ₹1,095.94 crore. This move follows management's earlier guidance on November 5, 2026, which outlined a planned Phase 1 capex of ₹1,000 crore for a greenfield site in Visakhapatnam.
The current non-binding MoU provides a 12-month window to finalize land acquisition and secure necessary regulatory approvals, aligning with the company's broader objective to enhance its domestic production capabilities.
Financial Performance and Order Visibility
- Reported a net profit of ₹102.52 crore for the quarter ended September 30, 2026, a 96.6 percent year-on-year increase
- Operating revenue for the same quarter surged 127.1 percent YoY to ₹375.74 crore
- The company maintains an operating profit margin of 31.6 percent as of the latest financial results
- Over 85 percent of total sales are secured by contracted volumes under annual and multi-year supply contracts
- Active bidding pipeline includes approximately 20 high-conviction RFPs across chronic therapies, oncology, and CNS
API Manufacturing Focus
The transition toward a new 50-acre facility underscores Blue Jet Healthcare's focus on the high-growth API segment. This development occurs as the company manages a robust CDMO pipeline with an expected 20 percent conversion rate, as reported in August 2026. While the stock has seen a 1-year price change of -7.27 percent, the recent quarterly momentum, characterized by 28.2 percent sequential revenue growth, suggests strong operational demand.
The proposed facility will be vital for servicing long-term contracts and expanding the company's reach in specialized therapeutic areas, provided the 12-month evaluation leads to definitive board and statutory approvals.
What to watch next
- Expiration of the 12-month non-binding MoU period on November 12, 2027
- Finalization of land acquisition for the 50-acre API facility in Andhra Pradesh
- Progress updates on the ₹1,000 crore greenfield Visakhapatnam site capex
- Next quarterly financial results announcement scheduled for early 2027
| Share price | ₹538.85 |
|---|---|
| Market capitalisation | ₹9,347.18 Cr |
| Revenue (annual) | ₹947.32 Cr |
| Net profit (annual) | ₹247.82 Cr |
| Revenue (latest quarter) | ₹375.74 Cr+28.19% vs previous quarter |
| Net profit (latest quarter) | ₹102.52 Cr+30.99% vs previous quarter |
| P/E (TTM) | 32.76×Sector 43.78× |
| Promoter holding | 73.15%-6.66% QoQ |
| FII holding | 0.81%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Blue Jet Healthcare Limited announcing the signing of a Memorandum of Understanding with the Andhra Pradesh Economic Development Board. Market figures from a third-party data provider.
